

GANYMED names 3 pharmaceutical industry executives to its Supervisory Board

Mainz, November 12, 2003

GANYMED Pharmaceuticals AG, an independent biotechnology company that identifies and validates antigen targets to improve therapeutics for life threatening diseases, today announced that its Supervisory Board has been expanded to include Björn H. Hoffstedt, Ph.D., M.D., Professor Dr. Med. Dr. h.c. Rolf Krebs, and John L. Ryan, Ph.D, M.D.

Dr. Hoffstedt has over 20 years of pharmaceutical drug discovery and development experience. Dr. Hoffstedt recently retired as the Chairman of the Supervisory Board of Genetics Institute GmbH, and gained earlier experience in various capacities at Merck, Bristol Meyers Squibb, and Pfizer. He is a founder of AB Clinical Development, which provides consultative services to a number of pharmaceutical companies. Dr. Hoffstedt received his Ph.D. in medicine and his M.D. from the University of Lund, Sweden.

Professor Krebs has over 25 years of pharmaceutical drug discovery and development experience. He is the Chairman of the Board of Managing Directors of Boehringer Ingelheim GmbH, where he has served in a number of capacities. Prior to joining Boehringer Ingelheim, he was Head of R&D Pharmaceuticals Worldwide for Bayer AG. Professor Krebs received his M.D. from the University of Mainz, Germany.

Dr. Ryan has over 15 years of pharmaceutical industry experience. He currently serves as Senior Vice President, Experimental Medicine at Wyeth, and was previously Executive Director Infectious Diseases – Clinical Research for Merck. Dr. Ryan received his Ph.D. in Molecular Biophysics from Yale University and his M.D. from the University of California at San Diego.

“I am extremely delighted and honored that we were able to attract directors with the world-class levels of both pharmaceutical industry and drug discovery and development experiences that Dr. Hoffstedt, Professor Krebs and Dr. Ryan have. The fact that GANYMED was able to attract this calibre of talent is a significant credibility event for the Company” said Felix Hofstetter, Chairman of GANYMED’s Supervisory Board and Managing Partner of Nextech Venture, the Company’s lead investor. “Our Board is now in a much better position to help GANYMED achieve the tremendous potential we believe it has. Our Board now consists of 3 pharmaceutical industry executives, 2 venture capitalists with a focus on life science investments, and 1 founder, who is a medical doctor specializing in oncology and responsible for the Oncology Department at the Johannes Gutenberg University Mainz”.

GANYMED Pharmaceuticals AG is an independent biotechnology company based in Mainz, Germany. GANYMED uses its proprietary technology to rapidly discover, identify and validate highly selective, disease specific cell-surface and intra-cellular antigens to accelerate the commercialization of highly effective therapeutics, initially in cancer, and also in the areas of both infectious and autoimmune diseases. GANYMED intends to become the preferred partner for pharmaceutical and biotechnology companies that develop monoclonal antibodies, small molecule compounds, vaccines, and diagnostic tools.

For further inquiries / contact:

GANYMED Pharmaceuticals AG

Dirk L. Sebastian, COO

Freiligrathstrasse 12

D-55131 Mainz

Germany

phone: (+49) 6131 / 1440 100

fax: (+49) 6131 / 1440 111

info@ganymed-pharmaceuticals.com